查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1585655

生物製藥 CMO/CRO 市場：供應商、服務類型、產品類型、業務規模、治療應用 - 2025-2030 年全球預測

Biopharmaceutical CMO & CRO Market by Source (Mammalian, Non-Mammalian), Service Type (Contract Manufacturing, Contract Research), Product, Scale of Operation, Therapeutic Applications - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年生物製藥CMO/CRO市場規模為813.2億美元，預計2024年將達到956.5億美元，2030年將成長至2,606.5億美元，複合年成長率為18.10%。

生物製藥委外研發機構（CMO）和委外研發機構（CRO）市場是藥物開發和製造連續體不可分割的一部分，推動藥物創新，同時緩解成本和產能限制。 CMO 提供從臨床前開發到商業生產的製造服務，而 CRO 提供研究服務，利用專業知識和分析工具加速開發新藥。隨著製藥公司在高度法規環境中努力縮短上市時間，這種共生關係變得越來越必要。應用包括生技藥品、生物相似藥、小分子和個人化醫療，最終用途產業從治療到疫苗。主要成長要素包括慢性病的流行、生技藥品和生物相似藥的進步、政府激勵措施以及尋求保持市場競爭力同時降低營運風險和成本的製藥公司的外包趨勢。最新的機會在於尋求與 CMO/CRO 合作以獲得利基技能和能力的生物技術新興企業的激增，以及新興市場對臨床試驗的需求不斷成長。然而，市場面臨複雜的監管環境、智慧財產權和品質保證問題等挑戰，這些挑戰往往限制無縫成長和擴充性。此外，市場也受到高度競爭格局和對技術純熟勞工的需求的影響，這使業務運作變得複雜。在利用人工智慧和機器學習最佳化流程、增強藥物開發和製造過程中資料主導的決策以及透過連續製造提高效率等領域，創新和研究的機會比比皆是。企業可以透過投資強大的品質源於設計 (QbD) 框架和資料分析來加強合規性並縮短時間，從而受益。該市場的特點是技術快速進步、競爭激烈和監管審查，使得業務敏捷性和適應性對於持續成長至關重要。

主要市場統計
基準年[2023] 813.2億美元
預測年份 [2024] 956.5億美元
預測年份 [2030] 2606.5億美元
複合年成長率（%） 18.10%

市場動態：針對快速發展的生物製藥 CMO/CRO 市場揭示的關鍵市場洞察

由於供需的動態互動，生物製藥 CMO/CRO 市場正在經歷轉型。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 製藥和生技領域外包需求不斷成長
    • 聚合物治療的潛在需求
    • 生物製藥領域的持續研發活動
  • 市場限制因素
    • 與外包公司較少和競爭較少有關的問題
  • 市場機會
    • 先進技術在生物技術領域的滲透
    • 用於標靶治療的細胞和基因療法的出現
  • 市場挑戰
    • CMO 和 CRO課責和品管問題

波特的五力：駕馭生物製藥 CMO/CRO 市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解生物製藥CMO/CRO市場的外部影響

外部宏觀環境因素在塑造生物製藥 CMO/CRO 市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解生物製藥 CMO/CRO 市場競爭狀況

生物製藥 CMO/CRO 市場的詳細市場佔有率分析提供了對供應商績效的全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 生物製藥 CMO/CRO 市場中的定位矩陣供應商績效評估

FPNV定位矩陣是評估生物製藥CMO/CRO市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議 規劃生物製藥 CMO/CRO 市場的成功之路

生物製藥 CMO/CRO 市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 製藥和生技領域對外包服務的需求不斷增加。
      • 聚合物治療的潛在需求
      • 生物製藥領域持續的研發活動
    • 抑制因素
      • 與外包供應商減少和競爭減少相關的問題
    • 機會
      • 尖端技術在生物技術領域的滲透
      • 用於標靶治療的細胞和基因療法的出現
    • 任務
      • CMO 和 CRO課責和品管問題
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 生物製藥 CMO/CRO 市場：依來源分類

  • 哺乳動物的
  • 非哺乳動物

第7章生物製藥CMO/CRO市場：依服務類型

  • 契約製造
  • 委託研究

第8章生物製藥 CMO/CRO 市場：依產品

  • 生物製藥
  • 生物相似藥

第9章依業務規模分類的生物製藥 CMO/CRO 市場

  • 臨床
  • 商業的

第10章 生物製藥CMO/CRO市場處理申請

  • 心血管疾病
  • 感染疾病
  • 神經病學
  • 腫瘤學
  • 眼科
  • 呼吸系統疾病

第11章美洲生物製藥CMO/CRO市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太生物製藥CMO/CRO市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲生物製藥CMO/CRO市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie, Inc.
  • arexel International Corporation
  • Baxter International Inc.
  • Boehringer Ingelheim Biopharmaceuticals GmbH
  • Boehringer Ingelheim GmbH
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • Eurofins Scientific Limited
  • FUJIFILM Diosynth Biotechnologies USA, Inc.
  • ICON Plc
  • KBI Biopharma, Inc.
  • KEMWELL BIOPHARMA PRIVATE LIMITED
  • Laboratory Corporation of America Holdings
  • Lonza Group AG
  • NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC
  • Patheon Inc.
  • Rentschler Biopharma SE
  • Sterling Pharma Solutions
Product Code: MRR-3A2E844FDA5E

The Biopharmaceutical CMO & CRO Market was valued at USD 81.32 billion in 2023, expected to reach USD 95.65 billion in 2024, and is projected to grow at a CAGR of 18.10%, to USD 260.65 billion by 2030.

The biopharmaceutical Contract Manufacturing Organization (CMO) and Contract Research Organization (CRO) markets have become essential in the drug development and manufacturing continuum, propelling pharmaceutical innovations while mitigating costs and capacity constraints. CMOs provide manufacturing services that range from pre-clinical development to commercial production, while CROs offer research services to aid clients in accelerating the development of new drugs through specialized knowledge and analytical tools. This symbiotic relationship is increasingly necessary as pharmaceutical companies strive to expedite time-to-market amidst stringent regulatory environments. The application scope includes biologics, biosimilars, small molecules, and personalized medicine, with end-use industries spanning therapeutics to vaccines. Key growth influencers include the rising prevalence of chronic diseases, advancements in biologics and biosimilars, governmental incentives, and the outsourcing trend by pharmaceutical companies eager to retain market competitiveness while lowering operational risks and costs. The latest opportunities lie in the surge of biotechnology startups seeking partnerships with CMOs/CROs for niche skill sets and capabilities, and the growing demand for clinical trials across emerging markets. Nevertheless, the market grapples with challenges such as complex regulatory landscapes, intellectual property concerns, and quality assurance issues, which often constrain seamless growth and scalability. Additionally, the market is impacted by high competition and the need for skilled labor, which complicate the operational landscapes. Innovation and research opportunities abound in areas like process optimization using artificial intelligence and machine learning, enhancing data-driven decision-making in drug development and manufacturing processes, and increasing efficiency through continuous manufacturing. Companies can benefit from investing in robust Quality by Design (QbD) frameworks and data analytics to enhance compliance and accelerate timelines. The market is characterized by rapid technological advancements, competitive collaboration, and regulatory scrutiny, making business agility and adaptability crucial for sustained growth.

KEY MARKET STATISTICS
Base Year [2023] USD 81.32 billion
Estimated Year [2024] USD 95.65 billion
Forecast Year [2030] USD 260.65 billion
CAGR (%) 18.10%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biopharmaceutical CMO & CRO Market

The Biopharmaceutical CMO & CRO Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising need for outsourced service in pharmaceutical and biotechnology sector
    • Potential demand for macromolecular therapeutics
    • Ongoing research and development activities in biopharmaceutical sector
  • Market Restraints
    • Issues pertinent to fewer outsource suppliers and less competition
  • Market Opportunities
    • Penetration of advanced technology in the biotechnology field
    • Emergence of Cell and Gene Therapies for Targeted Treatment
  • Market Challenges
    • Concern associated with accountability and quality control of CMO and CRO

Porter's Five Forces: A Strategic Tool for Navigating the Biopharmaceutical CMO & CRO Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biopharmaceutical CMO & CRO Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biopharmaceutical CMO & CRO Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biopharmaceutical CMO & CRO Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biopharmaceutical CMO & CRO Market

A detailed market share analysis in the Biopharmaceutical CMO & CRO Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biopharmaceutical CMO & CRO Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biopharmaceutical CMO & CRO Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biopharmaceutical CMO & CRO Market

A strategic analysis of the Biopharmaceutical CMO & CRO Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biopharmaceutical CMO & CRO Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., arexel International Corporation, Baxter International Inc., Boehringer Ingelheim Biopharmaceuticals GmbH, Boehringer Ingelheim GmbH, Catalent, Inc., Charles River Laboratories International, Inc., Eurofins Scientific Limited, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., ICON Plc, KBI Biopharma, Inc., KEMWELL BIOPHARMA PRIVATE LIMITED, Laboratory Corporation of America Holdings, Lonza Group AG, NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC, Patheon Inc., Rentschler Biopharma SE, and Sterling Pharma Solutions.

Market Segmentation & Coverage

This research report categorizes the Biopharmaceutical CMO & CRO Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Source, market is studied across Mammalian and Non-Mammalian.
  • Based on Service Type, market is studied across Contract Manufacturing and Contract Research.
  • Based on Product, market is studied across Biologics and Biosimilars.
  • Based on Scale of Operation, market is studied across Clinical and Commercial.
  • Based on Therapeutic Applications, market is studied across Cardiovascular Diseases, Infectious Disease, Neurology, Oncology, Ophthalmology, and Respiratory Disorder.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising need for outsourced service in pharmaceutical and biotechnology sector
      • 5.1.1.2. Potential demand for macromolecular therapeutics
      • 5.1.1.3. Ongoing research and development activities in biopharmaceutical sector
    • 5.1.2. Restraints
      • 5.1.2.1. Issues pertinent to fewer outsource suppliers and less competition
    • 5.1.3. Opportunities
      • 5.1.3.1. Penetration of advanced technology in the biotechnology field
      • 5.1.3.2. Emergence of Cell and Gene Therapies for Targeted Treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Concern associated with accountability and quality control of CMO and CRO
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Biopharmaceutical CMO & CRO Market, by Source

  • 6.1. Introduction
  • 6.2. Mammalian
  • 6.3. Non-Mammalian

7. Biopharmaceutical CMO & CRO Market, by Service Type

  • 7.1. Introduction
  • 7.2. Contract Manufacturing
  • 7.3. Contract Research

8. Biopharmaceutical CMO & CRO Market, by Product

  • 8.1. Introduction
  • 8.2. Biologics
  • 8.3. Biosimilars

9. Biopharmaceutical CMO & CRO Market, by Scale of Operation

  • 9.1. Introduction
  • 9.2. Clinical
  • 9.3. Commercial

10. Biopharmaceutical CMO & CRO Market, by Therapeutic Applications

  • 10.1. Introduction
  • 10.2. Cardiovascular Diseases
  • 10.3. Infectious Disease
  • 10.4. Neurology
  • 10.5. Oncology
  • 10.6. Ophthalmology
  • 10.7. Respiratory Disorder

11. Americas Biopharmaceutical CMO & CRO Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Biopharmaceutical CMO & CRO Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Biopharmaceutical CMO & CRO Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie, Inc.
  • 2. arexel International Corporation
  • 3. Baxter International Inc.
  • 4. Boehringer Ingelheim Biopharmaceuticals GmbH
  • 5. Boehringer Ingelheim GmbH
  • 6. Catalent, Inc.
  • 7. Charles River Laboratories International, Inc.
  • 8. Eurofins Scientific Limited
  • 9. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • 10. ICON Plc
  • 11. KBI Biopharma, Inc.
  • 12. KEMWELL BIOPHARMA PRIVATE LIMITED
  • 13. Laboratory Corporation of America Holdings
  • 14. Lonza Group AG
  • 15. NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC
  • 16. Patheon Inc.
  • 17. Rentschler Biopharma SE
  • 18. Sterling Pharma Solutions

LIST OF FIGURES

  • FIGURE 1. BIOPHARMACEUTICAL CMO & CRO MARKET RESEARCH PROCESS
  • FIGURE 2. BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. BIOPHARMACEUTICAL CMO & CRO MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. BIOPHARMACEUTICAL CMO & CRO MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOPHARMACEUTICAL CMO & CRO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOPHARMACEUTICAL CMO & CRO MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NON-MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CONTRACT MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CONTRACT RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESPIRATORY DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 235. BIOPHARMACEUTICAL CMO & CRO MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 236. BIOPHARMACEUTICAL CMO & CRO MARKET, FPNV POSITIONING MATRIX, 2023